The Nan Fung-backed neurological disorder treatment developer has raised $135m in funding in the past two years.
US-based neurological disorder therapy developer Aptinyx has filed for an $80m initial public offering that will enable property developer Nan Fung Group to exit.
Founded in 2015, Aptinyx is working on synthetic small molecules in order to treat disorders affecting the brain and nervous system.
The IPO proceeds will fund phase 2 clinical trials for its lead product candidate, NYX-2925, in a nerve disorder known as diabetic peripheral neuropathy, and fibromyalgia, a condition that causes pain throughout the body.
…
